Pigment-Dispersion Syndrome Clinical Trials

Find Pigment-Dispersion Syndrome Clinical Trials Near You

A Multi-center, Prospective, Cohort Expansion Clinical Study Evaluating the Safety, Usability, Implantation Accuracy and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma (STAR VII Study)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+. In Part 1, three different investigational insertion tools will be used to place MINIject implants in this first-in man study. Each arm represents a different version of the insertion tool. Subject and independent central reader will be blinded to the insertion tool used to implant MINIject S+. Part 2 will be an expansion phase where the selected insertion tool will be assessed in a larger population of subjects with open angle glaucoma and operable cataracts undergoing combined glaucoma and cataract surgery (with IOL implantation).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:

• Males or females, 20 years of age or older

• Diagnosis of open angle glaucoma (OAG) in the study eye

• Iridocorneal angle grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System in all quadrants of the study eye. (For subject's undergoing combined cataract extraction (with IOL implantation) with MINIject implantation, a grade 2 angle is acceptable prior to cataract surgery so long is the angle becomes grade 3 or greater prior to MINIject implantation).

• Glaucoma not adequately controlled with at least one topical hypotensive medication(s), unless the subject has an allergy / intolerance to a medication or inability to consistently access medication. Examples include but are not limited to prostaglandins, beta blockers, carbonic anhydrase inhibitors or alpha-2-agonists

• Minimal visual acuity in the study eye must be 35 letters EDTRS (20/200) or better and 50 letters ETDRS (20/100) or better in the fellow eye

• Maximal C/D ratio must be 0.9 in the study eye

• Subjects must be willing and able to follow study instructions and to return for scheduled study-related examinations

• Subjects must provide written informed consent prior to any study procedures

• Part 2 Only: Operable age-related cataract eligible for phacoemulsification surgery with Intraocular Lens (IOL) implantation

⁃ Part 2 Only: The following intraoperative criteria following the IOL implantation need to be met in order for investigator to proceed with the investigational device placement:

∙ Capsulorhexis is intact and centered

‣ Posterior capsular bag is intact

‣ The IOL is well-centered in the capsular bag

‣ There is no evidence of zonular dehiscence/rupture

‣ The Anterior Chamber (AC) angle was able to be clearly visualized using direct gonioscopy.

Locations
Other Locations
Honduras
Los Robles Vision d/b/a Centro Oftalmológico Robles
RECRUITING
Santa Rosa De Copán
United Kingdom
Colchester General Hospital
RECRUITING
Colchester
Diana, Princess of Wales Hospital
RECRUITING
Grimsby
Royal Liverpool University Hospital
RECRUITING
Liverpool
St Thomas' Hospital
RECRUITING
London
Contact Information
Primary
Delphine Hanot Mambres, PhD
delphine.hanot@istar-medical.com
0032472384955
Backup
Sabine Glibert
sabine.glibert@istar-medical.com
0032476609408
Time Frame
Start Date: 2025-09-29
Estimated Completion Date: 2028-07
Participants
Target number of participants: 60
Treatments
Active_comparator: Investigational device FG300X
One version of delivery tool
Active_comparator: Investigational device FG300Y
One version of delivery tool
Active_comparator: Investigational device FG300Z
One version of delivery tool
Sponsors
Leads: iSTAR Medical

This content was sourced from clinicaltrials.gov